THERAPY DOSSIER · th-45d64d89e955

miR-92b-3p mimic

Other · Synthetic microRNA mimic; no ChEMBL entity.

Evidence & regulatory context

Mechanism: Synthetic microRNA mimic; no ChEMBL entity.
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31120592 ↗2019Reported benefit

MiR-92b-3p promotes neurite growth and functional recovery via the PTEN/AKT pathway in acute spinal cord injury.

RatSpinal cord injuryUnspecifiedSprague-Dawley

Model: Acute spinal cord injury model in adult rats, with parallel in vitro work in PC12 cells

miR-92b-3p was downregulated after acute spinal cord injury while PTEN increased, and overexpression of miR-92b-3p reduced PTEN, increased AKT phosphorylation and raised GAP43 and NF-200 expression in PC12 cells and in vivo, improving Basso, Beattie and Bresnahan locomotor scores; the effect was bl…

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…